Analysis method for increasing susceptibility to sorafenib treatment in hepatocellular carcinoma
AssigneeCbsbioscience Co., Ltd
InventorsJin-Young PARK, Hee-Jung WANG
Life of this patent
Estimating the term…
Abstract
Provided is an analytical method of providing an information for diagnosis of a hepatocellular carcinoma patient having susceptibility to sorafenib, wherein the expression levels of eight genes, i.e., CDH1, CHAD, EFNA2, FANCC, MAP2K1, MEN1, PBRM1, and PPARG genes, in combination, are measured in carcinoma tissues of a hepatocellular carcinoma patient, and thereby the response (susceptibility) to sorafenib can be predicted with high accuracy, and the combination of said genes can be usefully applied as a biomarker for selecting a hepatocellular carcinoma patient having susceptibility to sorafenib.
Claims2
An analytical method of providing an information for diagnosis of a hepatocellular carcinoma patient having susceptibility to sorafenib, the method of which comprises measuring expression levels of CDH1, CHAD, EFNA2, FANCC, MAP2K1, MEN1, PBRM1, and PPARG genes, in carcinoma tissue samples which are externally discharged from the hepatocellular carcinoma patient, respectively.
Dependencies are inferred from the claim text.